FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 621 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... April 16, 2019 Test Detects Early Signs of Remaining Cancer in Kids Treated for... December 8, 2021 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 Load more HOT NEWS Patients less likely to rate cancer care as ‘very good’ during... 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... The Gift of Time ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive...
